Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Expecting tangible news soon
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(52)
•••
Comment by M101on May 30, 2022 3:17pm
123 Views
Post# 34717825

RE:RE:RE:RE:RE:RE:Expecting tangible news soon

RE:RE:RE:RE:RE:RE:Expecting tangible news soon
So why wait? Because things can always get worse, disaster capitalism is coming home to the USA.

Normal risk management practices imply that FSG is waiting for some confirmation of their early investment, they can do that here and still be ahead of momentum investors when time comes to double down because retail investors are not looking for biomarker success as defined by some esoteric medical community, Biogen has made sure of that.
P1 is nominally about safety, but if you're a long term investor here you've already discounted safety as a risk because the core hypothesis is based on selectivity, so you're only looking at P1 to provide a proxy for efficacy. If safety turns out to be an issue at all then Promis is toast.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities